What is it about?
The work is to improve bioavailability, safety and antibacterial potential of clarithromycin
Featured Image
Why is it important?
The major obstacles for treatment of intracellular infections with clarithromycin are poor gastrointestinal solubility, short half-life (3–4 h), low oral bioavailability and hepatotoxicity. Therefore, clarithromycin loaded solid lipid nanocarriers (CLA-SLNs) were engineered by an emulsification solvent evaporation method to improve CLA in vivo pharmacokinetics and safety.
Perspectives
Clarithromycin solid lipid nanoparticles can serve as a superior carrier system with high oral bioavailability of clarithromycin and can improve the therapeutic potential of clarithromycin in treatment of intracellular infections.
Manu Sharma
Banasthali Vidyapith
Read the Original
This page is a summary of: Implications of designing clarithromycin loaded solid lipid nanoparticles on their pharmacokinetics, antibacterial activity and safety, RSC Advances, January 2016, Royal Society of Chemistry,
DOI: 10.1039/c6ra12841f.
You can read the full text:
Contributors
The following have contributed to this page
